Resumen
Sulfated disaccharides for the treatment of neuropathic pain. The present invention relates to the use of sulphated disaccharides of formula (1) for the treatment of neuropathic pain. The present invention also relates to a pharmaceutical composition comprising the compound of formula (1) and at least one pharmaceutically acceptable excipient for use in the treatment of neuropathic pain. The compounds of formula (1) were effective in various experimental models of neuropathic pain, so that said compounds can be used effectively for the treatment of various types of neuropathic pain and their clinical manifestations, for example, mechanical allodynia or allodynia to the cold. (Machine-translation by Google Translate, not legally binding)
Reivindicaciones
1. - A compound of formula (I): <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0007" /> wherein: - R<1> is selected from among hydrogen, linear or branched C<1>-C<4> alkyl, phenylalkyl of less than 10 carbon atoms and -COCH<3>; - R<2> is selected from among hydrogen, -COCH<3> and -SO<3>Y; - R<3> is selected from among hydrogen, linear or branched C<1>-C<4> alkyl, phenylalkyl of less than 10 carbon atoms,-COCH<3> and -COPh, where Ph is phenyl; - G is selected from among -COOR<4> and -COOY; - A and B are selected, independently from each other, from among hydrogen, -SO<3>H,-SO<3>Y and -COCH<3>; wherein necessarily A or B is either -SO<3>H, or -SO<3>Y, R<4> is selected from among hydrogen, C<1>-C<2> alkyl and arylalkyl of less than 16 carbon atoms, and Y is an organic or inorganic cation; or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of neuropathic pain. 2. - The compound for use according to claim 1, characterized in that: - R<1> is selected from among hydrogen and linear C<1>-C<4> alkyl, and - G is selected from among -COOR<4> and -COOY, wherein R<4> is hydrogen or C<1>-C<2> alkyl and Y is an inorganic cation. 3. - The compound for use according to claim 2, characterized in that R<1> is hydrogen, R<2> is -COCH<3> and R<3> is hydrogen. 4. - The compound for use according to claim 2, characterized in that R<1> is methyl, R<2> is -COCH<3> and R<3> is hydrogen. 5. - The compound for use according to any of claims 3 or 4, characterized in that A is hydrogen, B is -SO<3>Y and G is -COOY, wherein Y is an inorganic cation. 6. - The compound for use according to any of claims 3 or 4, characterized in that A is -SO<3>Y, B is hydrogen, and G is -COOY, wherein Y is an inorganic cation. 7. - The compound for use according to any of claims 3 or 4, characterized in that A and B are-SOsY and G is -COOY, wherein Y is an inorganic cation. 8. - The compound for use according to claim 1, characterized in that the compound of formula (I) is chosen from among the group made up of the following compounds: <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0008" /> <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0009" /> and <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0010" /> 9. - The compound for use according to claim 1, characterized in that the compound of formula (I) is: <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0011" /> 10. - The compound for use according to any of claims 1 to 9, characterized in that the neuropathic pain is chosen from among: diabetic neuropathy, postherpetic neuralgia, neuropathy induced by chemotherapy, HIV-related neuropathy, rheumatoid arthritis-related neuropathy, osteoarthritis-related neuropathy, fibromyalgia-related neuropathy, trigeminal neuralgia, glossopharyngeal neuralgia, sphenopalatine ganglion neuralgia, vidian nerve neuralgia, persistent idiopathic facial pain, primary atypical facial neuralgia, pain related to phantom limbs, cerebral vascular post-accident pain, post-surgical pain syndrome, pain from multiple sclerosis and pain from spinal cord injuries. 11. - The compound for use according to claim 10, characterized in that the neuropathic pain is chosen from among: diabetic neuropathy, postherpetic neuralgia, neuropathy induced by chemotherapy and fibromyalgia-related neuropathy. 12. - The compound for use according to any of claims 1 to 11, characterized in that the treatment of the neuropathic pain relates to reversing or preventing the symptoms of mechanical allodynia or cold allodynia. 13. - A pharmaceutical composition comprising a compound of formula (I), as defined in any of claims 1 to 9, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of neuropathic pain.
